Omega Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Ravi Mehrotra of Omega Therapeutics acquired 50,000 stock options at an exercise price of $0.949 on December 3, 2024.
Omega Therapeutics' Chief Scientific Officer, Jennifer Ann Nelson, has been granted 110,000 stock options with a vesting schedule starting in November 2025.
Omega Therapeutics' CEO, Kaan Certel, was granted 340,000 stock options with a vesting schedule starting in 2025.
Robert L. Rosiello, a director of Omega Therapeutics, Inc., acquired 50,000 stock options on October 2, 2024.
Director Mary Szela acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.
Director Rainer J. Boehm reports the acquisition of stock options in Omega Therapeutics, Inc.
Director Christian Schade acquired 25,000 stock options in Omega Therapeutics on June 20, 2024, according to a Form 4 filing.
Director John Mendlein acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.
Director Elliott M. Levy acquired 25,000 stock options in Omega Therapeutics, Inc.
Director Richard A. Young acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.
Director Michelle C. Werner acquired 25,000 stock options in Omega Therapeutics, Inc. on June 20, 2024.
Director Richard N. Kender acquired stock options for 50,000 shares of Omega Therapeutics, Inc. on June 20, 2024.
Kaan Certel, Chief Business Officer of Omega Therapeutics, acquired 220,000 stock options on May 31, 2024.